News

NeuroSearch has signed a drug discovery and drug development agreement with Janssen Pharmaceutica (Janssen). As per the agreement, NeuroSearch and Janssen will collaborate to discover, develop and commercialise

Amgen has reported positive top-line results from a phase 3 trial evaluating Vectibix (panitumumab) in combination with Folfiri (an irinotecan-based chemotherapy) as a second-line treatment in 1,186 patients

Novartis has received FDA approval for Extavia (interferon beta-1b), the first in a new planned portfolio of multiple sclerosis (MS) medicines from the company. Extavia is approved by

Eli Lilly has reported that the US District Court for the Eastern District of Michigan has granted a motion by Sun Pharmaceuticals for partial summary judgment. Reportedly, the

BioLife Solutions has entered into a non-exclusive distribution agreement with StemCell Technologies. Mike Rice, chairman and CEO of BioLife, said: We’re very pleased to now have our products

Labopharm has commented on the outcome of patent-infringement litigation initiated by Purdue Pharma Products against Par Pharmaceutical, relating to Ultram ER (tramadol hydrochloride extended-release tablets). The patents-in-suit are

GlaxoSmithKline (GSK) has signed a partnership with Oswaldo Cruz Foundation (Fiocruz) to develop and manufacture vaccines for pressing public health priorities in Brazil. The agreement will establish a

Epeius’ Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The Fast Track Product designation

A new consortium has been formed to boost drug development for the treatment of two diseases, African sleeping sickness and leishmaniasis. Reportedly, the new consortium will target parasite-specific